Community Acquired Pneumonia Pipeline Review, H2 2018 - Therapeutic Assessment of 15 Companies & Drug Profiles - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Community Acquired Pneumonia - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Community Acquired Pneumonia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 1, 6, 2, 2 and 1 respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Community Acquired Pneumonia - Overview Community Acquired Pneumonia - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Community Acquired Pneumonia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Community Acquired Pneumonia - Companies Involved in Therapeutics Development Biotest AG InflaRx NV ioGenetics Inc Kyorin Pharmaceutical Co Ltd Meiji Seika Pharma Co Ltd Melinta Therapeutics Inc Merck & Co Inc Nabriva Therapeutics plc Paratek Pharmaceuticals Inc ProThera Biologics Inc TaiGen Biotechnology Co Ltd Takeda Pharmaceutical Co Ltd Tetraphase Pharmaceuticals Inc TiGenix NV Wockhardt Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/225p88/community?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006084/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Infectious Diseases Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 05:57 PM/DISC: 09/26/2018 05:57 PM


Update hourly